<!DOCTYPE html>
<html lang="zh-Hant" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>巴菲特AI價值投資-諾和諾德(Novo Nordisk)口服Wegovy研究報告</title>
    <!-- Tailwind CSS -->
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- Chart.js -->
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        .active-nav-link {
            color: #0ea5e9; /* sky-500 */
            border-bottom: 2px solid #0ea5e9;
        }
        .inactive-nav-link {
            color: #44403c; /* stone-700 */
        }
        /* 表格固定表頭 */
        .sticky-table-header th {
            position: sticky;
            top: 0;
            z-index: 10;
            background-color: #f8fafc;
        }
    </style>
</head>
<body class="bg-stone-50 text-stone-800 font-sans leading-relaxed">

    <!-- Sticky Header & Navigation -->
    <header class="bg-white/90 backdrop-blur-md shadow-sm sticky top-0 z-50">
        <nav class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex justify-between h-16 items-center">
                <div class="flex-shrink-0 flex items-center">
                    <span class="text-xl font-bold text-sky-600">諾和諾德口服Wegovy研究</span>
                </div>
                
                <!-- Desktop Menu -->
                <div class="hidden md:flex space-x-8">
                    <a href="#market-trends" class="nav-link px-1 py-2 text-sm font-medium transition-colors inactive-nav-link">市場趨勢</a>
                    <a href="#product-potential" class="nav-link px-1 py-2 text-sm font-medium transition-colors inactive-nav-link">產品潛力</a>
                    <a href="#financial-impact" class="nav-link px-1 py-2 text-sm font-medium transition-colors inactive-nav-link">財報分析</a>
                    <a href="#competitor-analysis" class="nav-link px-1 py-2 text-sm font-medium transition-colors inactive-nav-link">競品比較</a>
                    <a href="#investment-advice" class="nav-link px-1 py-2 text-sm font-medium transition-colors inactive-nav-link">綜合評估</a>
                </div>

                <!-- Mobile Menu Button -->
                <div class="md:hidden flex items-center">
                    <button id="mobile-menu-button" class="text-stone-600 hover:text-sky-600 focus:outline-none">
                        <svg class="h-6 w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16m-7 6h7" />
                        </svg>
                    </button>
                </div>
            </div>
        </nav>
        <!-- Mobile Menu Content -->
        <div id="mobile-menu" class="hidden md:hidden bg-white border-t border-stone-100 px-4 py-4 space-y-2">
            <a href="#market-trends" class="block px-3 py-2 rounded-md text-base font-medium text-stone-700 hover:bg-sky-50">市場趨勢</a>
            <a href="#product-potential" class="block px-3 py-2 rounded-md text-base font-medium text-stone-700 hover:bg-sky-50">產品潛力</a>
            <a href="#financial-impact" class="block px-3 py-2 rounded-md text-base font-medium text-stone-700 hover:bg-sky-50">財報分析</a>
            <a href="#competitor-analysis" class="block px-3 py-2 rounded-md text-base font-medium text-stone-700 hover:bg-sky-50">競品比較</a>
            <a href="#investment-advice" class="block px-3 py-2 rounded-md text-base font-medium text-stone-700 hover:bg-sky-50">綜合評估</a>
        </div>
    </header>

    <main class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-10">
        
        <!-- Hero Section -->
        <section class="mb-16 text-center">
            <h1 class="text-4xl md:text-5xl font-extrabold text-stone-900 mb-4">美 FDA 核准口服 Wegovy</h1>
            <p class="text-xl text-stone-600 max-w-3xl mx-auto">深度研究報告：探討諾和諾德（Novo Nordisk）營收影響與全球 GLP-1 減重市場佈局</p>
        </section>

        <!-- Market Trends Section -->
        <section id="market-trends" class="mb-20 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">GLP-1 減重藥市場成長趨勢</h2>
            <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-xl font-semibold mb-4 text-sky-700">市場規模預測</h3>
                    <p class="mb-4 text-stone-600 text-justify">
                        分析師預期，到 2030 年代初全球肥胖治療市場規模可達約 <span class="font-bold text-stone-800">1,500 億美元</span>。目前 GLP-1 類藥物（如 Wegovy、Zepbound）正引領一場醫療變革。
                    </p>
                    <div class="space-y-4">
                        <div class="flex items-center p-3 bg-sky-50 rounded-lg">
                            <div class="bg-sky-500 text-white p-2 rounded-md mr-4 font-bold">131%</div>
                            <div>
                                <p class="text-sm text-stone-500">禮來 Tirzepatide (2025 Q3)</p>
                                <p class="font-bold text-stone-800">單季營收成長率</p>
                            </div>
                        </div>
                        <div class="flex items-center p-3 bg-emerald-50 rounded-lg">
                            <div class="bg-emerald-500 text-white p-2 rounded-md mr-4 font-bold">37%</div>
                            <div>
                                <p class="text-sm text-stone-500">諾和諾德 (2025 前三季)</p>
                                <p class="font-bold text-stone-800">肥胖護理板塊成長率</p>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-xl font-semibold mb-4 text-sky-700">營收對比圖 (2025 Q3)</h3>
                    <div class="relative h-64 w-full">
                        <canvas id="marketShareChart"></canvas>
                    </div>
                </div>
            </div>
        </section>

        <!-- Product Potential Section -->
        <section id="product-potential" class="mb-20 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">口服 Wegovy 的市場潛力與優勢</h2>
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="bg-white rounded-lg shadow-md p-6 border-t-4 border-sky-500 hover:shadow-xl transition-shadow">
                    <p class="text-sm text-stone-500 mb-1">關鍵試驗減重效果</p>
                    <h4 class="text-2xl font-bold text-sky-600 mb-2">16.6%</h4>
                    <p class="text-sm text-stone-600">64週平均體重減輕，效果媲美注射劑型。</p>
                </div>
                <div class="bg-white rounded-lg shadow-md p-6 border-t-4 border-sky-500 hover:shadow-xl transition-shadow">
                    <p class="text-sm text-stone-500 mb-1">口服劑型定價</p>
                    <h4 class="text-2xl font-bold text-sky-600 mb-2">$149 / 月</h4>
                    <p class="text-sm text-stone-600">大幅降低門檻，為目前最實惠的 GLP-1 選擇。</p>
                </div>
                <div class="bg-white rounded-lg shadow-md p-6 border-t-4 border-sky-500 hover:shadow-xl transition-shadow">
                    <p class="text-sm text-stone-500 mb-1">物流與儲存</p>
                    <h4 class="text-2xl font-bold text-sky-600 mb-2">無需冷藏</h4>
                    <p class="text-sm text-stone-600">每日口服藥丸，降低生產、運輸與患者使用難度。</p>
                </div>
            </div>
            
            <!-- Comparison Table Section -->
            <div class="bg-white rounded-lg shadow-lg p-6 overflow-hidden">
                <h3 class="text-xl font-semibold mb-6 text-sky-700">諾和諾德 vs. 禮來：口服減重藥關鍵參數</h3>
                
                <!-- Search Input -->
                <div class="mb-6">
                    <div class="relative max-w-xs">
                        <input type="text" id="tableFilter" class="w-full pl-10 pr-4 py-2 border rounded-lg focus:ring-2 focus:ring-sky-500 focus:outline-none" placeholder="搜尋關鍵字...">
                        <div class="absolute left-3 top-2.5 text-stone-400">
                            <svg class="h-5 w-5" fill="none" viewBox="0 0 24 24" stroke="currentColor">
                                <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z" />
                            </svg>
                        </div>
                    </div>
                </div>

                <div class="overflow-x-auto">
                    <table class="min-w-full divide-y divide-stone-200" id="comparisonTable">
                        <thead class="bg-stone-50 sticky-table-header">
                            <tr>
                                <th class="px-6 py-3 text-left text-xs font-bold text-stone-500 uppercase tracking-wider">比較項目</th>
                                <th class="px-6 py-3 text-left text-xs font-bold text-stone-500 uppercase tracking-wider">諾和諾德 (Wegovy 口服)</th>
                                <th class="px-6 py-3 text-left text-xs font-bold text-stone-500 uppercase tracking-wider">禮來 (Orforglipron)</th>
                            </tr>
                        </thead>
                        <tbody class="bg-white divide-y divide-stone-200" id="tableBody">
                            <!-- JS content here -->
                        </tbody>
                    </table>
                </div>
            </div>
        </section>

        <!-- Financial Impact Section -->
        <section id="financial-impact" class="mb-20 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">財報觀點：營收與業績影響</h2>
            <div class="bg-white rounded-lg shadow-lg p-8">
                <div class="grid grid-cols-1 md:grid-cols-2 gap-12 items-center">
                    <div>
                        <ul class="space-y-4">
                            <li class="flex items-start">
                                <div class="bg-sky-100 p-2 rounded-full mr-4 text-sky-600 font-bold">1</div>
                                <div>
                                    <h5 class="font-bold text-stone-800">業務轉機</h5>
                                    <p class="text-sm text-stone-600 text-justify">口服版預計於 2026 年中顯著帶動營收曲線回升，扭轉目前增速放緩的頹勢。</p>
                                </div>
                            </li>
                            <li class="flex items-start">
                                <div class="bg-sky-100 p-2 rounded-full mr-4 text-sky-600 font-bold">2</div>
                                <div>
                                    <h5 class="font-bold text-stone-800">以價換量</h5>
                                    <p class="text-sm text-stone-600 text-justify">注射劑型主動降價 70%，旨在換取醫療保險覆蓋及擴大自費市場佔有率。</p>
                                </div>
                            </li>
                            <li class="flex items-start">
                                <div class="bg-sky-100 p-2 rounded-full mr-4 text-sky-600 font-bold">3</div>
                                <div>
                                    <h5 class="font-bold text-stone-800">潛在新增用戶</h5>
                                    <p class="text-sm text-stone-600 text-justify">吸引對注射有恐懼感的族群，淨增處方量可望遠超現有產品內部替換造成的損失。</p>
                                </div>
                            </li>
                        </ul>
                    </div>
                    <div class="bg-stone-50 p-6 rounded-xl border border-stone-200">
                        <h4 class="text-lg font-bold mb-4 text-center">諾和諾德年度營收增長預期 (CER)</h4>
                        <div class="h-64">
                            <canvas id="growthForecastChart"></canvas>
                        </div>
                    </div>
                </div>
            </div>
        </section>

        <!-- Investment Advice -->
        <section id="investment-advice" class="mb-10 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">投資分析與建議</h2>
            <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                <div class="bg-emerald-50 rounded-lg p-6 border-l-8 border-emerald-500">
                    <h3 class="text-xl font-bold text-emerald-800 mb-4 flex items-center">
                        <svg class="h-6 w-6 mr-2" fill="none" viewBox="0 0 24 24" stroke="currentColor">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z" />
                        </svg>
                        已持有股票者：續抱/逢低加碼
                    </h3>
                    <ul class="list-disc list-inside text-emerald-900 space-y-2 text-sm">
                        <li>目前預估本益比約 13 倍，處於歷史低點區間。</li>
                        <li>2026 年盈餘增速預期達 15% 以上。</li>
                        <li>配息率約 3.3%，提供良好的下檔保護與現金收益。</li>
                    </ul>
                </div>
                <div class="bg-sky-50 rounded-lg p-6 border-l-8 border-sky-500">
                    <h3 class="text-xl font-bold text-sky-800 mb-4 flex items-center">
                        <svg class="h-6 w-6 mr-2" fill="none" viewBox="0 0 24 24" stroke="currentColor">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z" />
                        </svg>
                        尚未持股者：分批佈局
                    </h3>
                    <ul class="list-disc list-inside text-sky-900 space-y-2 text-sm">
                        <li>市場對競爭疑慮已大部分反映在股價中。</li>
                        <li>2026 年為業績與股價的轉折年，適合分批買入。</li>
                        <li>建議設定 3-5 年中長期投資週期，參與肥胖治療浪潮。</li>
                    </ul>
                </div>
            </div>
        </section>

    </main>

    <!-- Footer -->
    <footer class="bg-stone-800 text-stone-300 mt-12 py-8">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 text-center">
            <p>&copy; 巴菲特AI價值投資-諾和諾德(Novo Nordisk)口服Wegovy研究報告。僅供參考，不構成投資建議。</p>
            <p class="text-xs mt-1">資料來源：基於網路中Novo Nordisk相關公開資料 (2025年12月30日)。</p>
        </div>
    </footer>

    <!-- Scripts -->
    <script>
        // 1. Data Definitions
        const productData = [
            { item: "作用機制", novo: "GLP-1受體激動劑 (胜肽類)", lilly: "GLP-1受體激動劑 (小分子)" },
            { item: "劑型與用法", novo: "口服片劑, 每日一次 (需空腹)", lilly: "口服片劑, 每日一次 (不限飲食)" },
            { item: "臨床減重效果", novo: "約 16.6% (64週)", lilly: "約 12.4% (26週)" },
            { item: "定價策略", novo: "約 $149/月 (起始劑量)", lilly: "預計採具競爭力定價" },
            { item: "FDA 審批狀態", novo: "已核准 (2025/12)", lilly: "加速審查中 (預計 2026/03)" },
            { item: "產品優勢", novo: "療效強勁, Wegovy 品牌力強", lilly: "服用方便, 小分子生產性高" }
        ];

        // 2. Initializing Table
        const tableBody = document.getElementById('tableBody');
        const tableFilter = document.getElementById('tableFilter');

        function renderTable(data) {
            tableBody.innerHTML = '';
            data.forEach(row => {
                const tr = document.createElement('tr');
                tr.innerHTML = `
                    <td class="px-6 py-4 whitespace-nowrap text-sm font-medium text-stone-900">${row.item}</td>
                    <td class="px-6 py-4 text-sm text-stone-600">${row.novo}</td>
                    <td class="px-6 py-4 text-sm text-stone-600">${row.lilly}</td>
                `;
                tableBody.appendChild(tr);
            });
        }

        renderTable(productData);

        // Filter Logic
        tableFilter.addEventListener('input', (e) => {
            const keyword = e.target.value.toLowerCase();
            const filtered = productData.filter(item => 
                item.item.toLowerCase().includes(keyword) || 
                item.novo.toLowerCase().includes(keyword) || 
                item.lilly.toLowerCase().includes(keyword)
            );
            renderTable(filtered);
        });

        // 3. Mobile Menu Toggle
        const menuBtn = document.getElementById('mobile-menu-button');
        const mobileMenu = document.getElementById('mobile-menu');
        menuBtn.addEventListener('click', () => {
            mobileMenu.classList.toggle('hidden');
        });

        // 4. Chart.js Implementation
        window.onload = function() {
            // Market Share / Revenue Chart (Bar)
            const ctx1 = document.getElementById('marketShareChart').getContext('2d');
            new Chart(ctx1, {
                type: 'bar',
                data: {
                    labels: ['Novo GLP-1 (前三季)', 'Lilly Tirzepatide (Q3)'],
                    datasets: [{
                        label: '營收 (億美元)',
                        data: [320, 101],
                        backgroundColor: ['#0ea5e9', '#10b981'],
                        borderRadius: 8,
                        barThickness: 50
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: { legend: { display: false } },
                    scales: {
                        y: { beginAtZero: true, title: { display: true, text: '十億美元' } }
                    }
                }
            });

            // Growth Forecast (Line)
            const ctx2 = document.getElementById('growthForecastChart').getContext('2d');
            new Chart(ctx2, {
                type: 'line',
                data: {
                    labels: ['2023', '2024', '2025E', '2026E'],
                    datasets: [{
                        label: '營收成長率 (%)',
                        data: [25, 20, 10, 18],
                        borderColor: '#0ea5e9',
                        backgroundColor: 'rgba(14, 165, 233, 0.1)',
                        fill: true,
                        tension: 0.4,
                        pointRadius: 6,
                        pointBackgroundColor: '#fff',
                        pointBorderColor: '#0ea5e9',
                        pointBorderWidth: 2
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: { legend: { display: false } },
                    scales: {
                        y: { 
                            beginAtZero: true, 
                            max: 30,
                            ticks: { callback: value => value + '%' }
                        }
                    }
                }
            });

            // 5. Scroll Intersection Observer for Active Link
            const sections = document.querySelectorAll('section[id]');
            const navLinks = document.querySelectorAll('.nav-link');

            const observerOptions = {
                root: null,
                rootMargin: '-20% 0px -70% 0px',
                threshold: 0
            };

            const observer = new IntersectionObserver((entries) => {
                entries.forEach(entry => {
                    if (entry.isIntersecting) {
                        const id = entry.target.getAttribute('id');
                        navLinks.forEach(link => {
                            link.classList.remove('active-nav-link');
                            link.classList.add('inactive-nav-link');
                            if (link.getAttribute('href') === `#${id}`) {
                                link.classList.add('active-nav-link');
                                link.classList.remove('inactive-nav-link');
                            }
                        });
                    }
                });
            }, observerOptions);

            sections.forEach(section => observer.observe(section));
        };
    </script>
</body>
</html>